Maria L. Karadima

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Our aim was to evaluate the predictive and prognostic influence of BRAF mutation and other molecular, clinical and laboratory parameters in stage IV colorectal cancer (CRC). 60 patients were included in this retrospective analysis, and 17 variables were examined for their relation with treatment response and survival. KRAS mutation was identified in 40.3 %(More)
  • 1